A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer

Metastatic Renal Cell Carcinoma Clinical Trial

Official title:

A Phase I Open-label Study to Evaluate Safety and Immunologic Response of COMBIG-DC Administered Intratumorally in Patients With Metastatic Renal Cell Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01525017
• Other study ID #: IM-101
• Secondary ID: 2011-002039-25
• Status: Completed
• Phase: Phase 1
• First received: January 20, 2012
• Last updated: October 9, 2015
• Start date: February 2012
• Est. completion date: December 2013

Study information

• Verified date: October 2015
• Source: Immunicum AB
• Contact: n/a
• Is FDA regulated: No
• Health authority: Sweden: Medical Products AgencySweden: Regional Ethical Review Board
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to answer the question "Is it possible to inject the Combig-DC vaccine in a renal tumour without getting unacceptable side effects"? Patients newly diagnosed with metastatic renal cell carcinoma will get Combig-DC vaccinations at two occasions in a two weeks period (day 1 and day 14). After another two weeks the kidney will be eliminated. Adverse events will be registered, as well as changes in vital signs(heart rate, blood pressure and body temperature) and lab parameters. Immunologic response will be evaluated by measuring immunologic markers in blood and tumour tissue, and measuring the size of the metastases three months after nephrectomy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: December 2013
• Est. primary completion date: December 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Be informed of the nature of the study and have provided written informed consent

2. At least 18 years of age.

3. Diagnosis of renal cell carcinoma with at least one distant metastasis, and/or one distant lymph node metastasis.

4. Tumor size (renal cell carcinoma; primary tumor) at least 4.0 cm in longest diameter as measured by CT. Distant metastasis at least 1 cm diameter as measured by CT or a distant lymph node metastasis at least 2,5 cm diameter as measured by CT. Clinical stage 'T1b or more; NX; M1'

5. Adequate hematological parameters, i.e:

B-Leukocyte count = 4.5 x 109/L B-Platelet count = 150 x109/L B-Haemoglobin = 100 g/L

6. Women of Childbearing Potential (WOCBP) should use adequate contraception (oral or injectable contraceptives, hormone releasing intrauterine device) throughout the study period.

Exclusion Criteria:

1. Performance status > ECOG 2 after optimization of analgesics

2. Adequate coagulation parameters, i.e: P-Prothrombin complex (PK), P-APT time

3. Ongoing treatment with systemic corticosteroids (inhaled, intranasal and local steroids accepted) within 28 days before first vaccination.

4. Previously known or ongoing active autoimmune disease which requires treatment with systemic immunosuppressive agents. E.g. inflammatory bowel disease, multiple sclerosis, sarcoidosis, psoriasis, autoimmune hemolytic anemia, rheumatoid arthritis, SLE, vasculitis, Sjögren's syndrome, scleroderma, autoimmune hepatitis, and other rheumatological diseases.

5. Patients with previous or ongoing skin malignancy (basal-cell carcinoma, squamous cell carcinoma, melanoma), other hematological or solid malignancy or blood dysfunctions.

6. Ongoing infection that requires treatment with antibiotics.

7. Known major reaction/adverse event in connection with previously made vaccination (e.g. asthma, anaphylaxis or other serious reaction)

8. Known malignancy in CNS.

9. Active or latent virus disease (HIV, HBV and HCV).

10. Ongoing pregnancy or lactation. Females needs to have negative pregnancy test at screening visit.

11. Life expectancy less than 3 months.

12. Concomitant exposure to other investigational products.

13. Any reason that, in the opinion of the investigator, contraindicates that the patient participates in the study.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Renal Cell
• Metastatic Renal Cell Carcinoma

Intervention

Biological:
• Combig-DC (allogeneic dendritic cells) Cancer Vaccine
Cryopreserved dendritic cell suspension of 10 million cells per ml in heat-inactivated plasma, supplemented with 10% dimethyl sulfoxide (DMSO).

Locations

Country	Name	City	State
Sweden	Dept of Oncology, University Hospital	Uppsala

Sponsors (1)

Lead Sponsor	Collaborator
Immunicum AB

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Registration of adverse events as a measure of safety and tolerability		1 year 3 months (Feb 2012-May 2013)	Yes
Primary	Changes in vital signs from baseline (heart rate, blood pressure, body temperature) as a measure of safety and tolerability		1 year 3 months (Feb 2012 - May 2013)	Yes
Primary	Changes in lab parameters from baseline as a measure of safety and tolerability		1 year 3 months (Feb 2012 - May 2013)	Yes
Secondary	Immunologic response in blood (immunologic panel) measured with ELISPOT.	Time for sampling: just before first injection and second injection, 2 weeks post second injection (in connection with the hospitalization for nephrectomy) and at 3 months post nephrectomy. ELISPOT assessment will be made at time of nephrectomy (after the second vaccination) at earliest.	1 year 3 months (Feb 2012 - May 2013)	No
Secondary	Examination of immunohistology parameters (macrophage marker, CD3, CD4, CD8, CD56) of the renal tumor post nephrectomy.		1 year 3 months (Feb 2012 - May 2013)	No
Secondary	CT-evaluation of the size of the metastasis(-es) 3 months post nephrectomy		1 year 3 months (Feb 2012 - March 2013)	No
Secondary	CT evaluation to evaluate number of metastases 3 months post nephrectomy.		1 year 3 months (Feb 2012 - May 2013)	No
Secondary	Changes in body weight 3 months post nephrectomy vs. baseline.		1 year 3 months (Feb 2012 - May 2013)	No
Secondary	Changes in WHO-ECOG 3 months post nephrectomy vs. baseline.		1 year 3 months (Feb 2012 - may 2013)	No